NASDAQ:TSVT 2seventy bio (TSVT) Stock Price, News & Analysis → With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad) Free TSVT Stock Alerts $5.06 +0.20 (+4.12%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$4.87▼$5.2050-Day Range$3.96▼$6.0052-Week Range$1.53▼$12.69Volume895,858 shsAverage Volume1.42 million shsMarket Capitalization$259.63 millionP/E RatioN/ADividend YieldN/APrice Target$13.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get 2seventy bio alerts: Email Address 2seventy bio MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside160.2% Upside$13.17 Price TargetShort InterestBearish14.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 8 Articles This WeekInsider TradingAcquiring Shares$3.14 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.39) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector271st out of 914 stocksPharmaceutical Preparations Industry106th out of 406 stocks 4.2 Analyst's Opinion Consensus Rating2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst Coverage2seventy bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.29% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in 2seventy bio has recently increased by 29.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield2seventy bio does not currently pay a dividend.Dividend Growth2seventy bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSVT. Previous Next 3.7 News and Social Media Coverage News Sentiment2seventy bio has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for 2seventy bio this week, compared to 3 articles on an average week.Search Interest22 people have searched for TSVT on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat Follows9 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 2seventy bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,143,100.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of 2seventy bio is held by insiders.Percentage Held by Institutions93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 2seventy bio are expected to grow in the coming year, from ($1.39) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 2seventy bio is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 2seventy bio is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio2seventy bio has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About 2seventy bio Stock (NASDAQ:TSVT)2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Read More TSVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSVT Stock News HeadlinesMarch 26, 2024 | insidertrades.comInsider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Buys 300,000 Shares of StockApril 17, 2024 | msn.com2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's WhyApril 17, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...April 15, 2024 | americanbankingnews.com2seventy bio, Inc. (NASDAQ:TSVT) Short Interest Up 29.7% in MarchApril 13, 2024 | morningstar.com2seventy bio Inc Ordinary SharesApril 11, 2024 | americanbankingnews.com2seventy bio, Inc. (NASDAQ:TSVT) to Post Q1 2024 Earnings of ($0.49) Per Share, Leerink Partnrs ForecastsApril 10, 2024 | investing.comCiti raises 2Seventy Bio stock target on FDA approvalApril 10, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on 2seventy bio, Inc.'s FY2028 Earnings (NASDAQ:TSVT)April 17, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...April 9, 2024 | americanbankingnews.comCitigroup Raises 2seventy bio (NASDAQ:TSVT) Price Target to $12.00April 8, 2024 | markets.businessinsider.comPositive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive DynamicsApril 7, 2024 | markets.businessinsider.comBuy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic OutlookApril 5, 2024 | msn.comBristol Myers Wins FDA Nod for AbecmaApril 5, 2024 | msn.comFDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary CancerApril 5, 2024 | seekingalpha.comBristol Myers, 2seventy bio's Abecma approved for earlier line multiple myelomaApril 5, 2024 | finance.yahoo.comU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyMarch 20, 2024 | msn.com2seventy bio appoints Eli Casdin and Charles Newton to its board of directorsMarch 20, 2024 | businesswire.com2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsMarch 20, 2024 | morningstar.comThinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?March 17, 2024 | marketwatch.comBristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee ApprovalMarch 16, 2024 | msn.comBristol Myers wins FDA AdCom backing for Abecma label expansionMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 2seventy bio (TSVT), Immuneering (IMRX)March 14, 2024 | marketwatch.com2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene TherapyMarch 7, 2024 | seekingalpha.com2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.com2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for 2seventy bio on FDA Meeting and Strong Financial OutlookMarch 7, 2024 | finance.yahoo.comDowngrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near TermSee More Headlines Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/17/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TSVT CUSIPN/A CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees274Year FoundedN/APrice Target and Rating Average Stock Price Target$13.17 High Stock Price Target$26.00 Low Stock Price Target$5.00 Potential Upside/Downside+160.2%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217,570,000.00 Net Margins-216.73% Pretax Margin-216.73% Return on Equity-59.19% Return on Assets-29.67% Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio3.98 Sales & Book Value Annual Sales$100.39 million Price / Sales2.59 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book1.00Miscellaneous Outstanding Shares51,310,000Free Float49,977,000Market Cap$259.63 million OptionableOptionable Beta1.84 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Nick Leschly (Age 51)President & Director Comp: $1.81MDr. Philip D. Gregory D. Phil. (Age 53)DPHIL, Chief Scientific Officer Comp: $1.01MMr. William D. Baird III (Age 52)M.B.A., Chief Executive Officer Comp: $810.83kVicki EatwellChief Financial OfficerJessica SnowSenior VP of Quality and Head of OperationsMs. Susan Abu-Absi Ph.D.Chief Technology OfficerMs. Teresa L. Jurgensen J.D.Senior VP, General Counsel & Corporate SecretaryMs. Kerri JensenHead of People & CultureMs. Jenn SnyderSenior Vice President of Corporate AffairsDr. Steven Bernstein M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsTelomir PharmaceuticalsNASDAQ:TELOXeris BiopharmaNASDAQ:XERSPuma BiotechnologyNASDAQ:PBYIAC ImmuneNASDAQ:ACIUFoghorn TherapeuticsNASDAQ:FHTXView All CompetitorsInsiders & InstitutionsWedmont Private CapitalBought 85,934 shares on 4/10/2024Ownership: 0.167%Casdin Capital, LlcBought 330,000 shares on 3/25/2024Total: $1.67 M ($5.07/share)Casdin Capital, LlcBought 300,000 shares on 3/21/2024Total: $1.47 M ($4.90/share)Vanguard Group Inc.Bought 251,893 shares on 3/11/2024Ownership: 7.768%Wellington Management Group LLPSold 2,478,516 shares on 3/5/2024Ownership: 1.019%View All Insider TransactionsView All Institutional Transactions TSVT Stock Analysis - Frequently Asked Questions Should I buy or sell 2seventy bio stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares. View TSVT analyst ratings or view top-rated stocks. What is 2seventy bio's stock price target for 2024? 8 analysts have issued 1-year price objectives for 2seventy bio's stock. Their TSVT share price targets range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $13.17 in the next twelve months. This suggests a possible upside of 160.2% from the stock's current price. View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts. How have TSVT shares performed in 2024? 2seventy bio's stock was trading at $4.27 at the beginning of the year. Since then, TSVT stock has increased by 18.5% and is now trading at $5.06. View the best growth stocks for 2024 here. Are investors shorting 2seventy bio? 2seventy bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,810,000 shares, an increase of 29.7% from the March 15th total of 5,250,000 shares. Based on an average daily volume of 1,450,000 shares, the short-interest ratio is currently 4.7 days. Currently, 14.3% of the company's stock are short sold. View 2seventy bio's Short Interest. When is 2seventy bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our TSVT earnings forecast. How were 2seventy bio's earnings last quarter? 2seventy bio, Inc. (NASDAQ:TSVT) posted its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.11. The business had revenue of $10.68 million for the quarter, compared to analysts' expectations of $13.91 million. 2seventy bio had a negative trailing twelve-month return on equity of 59.19% and a negative net margin of 216.73%. During the same period in the prior year, the business earned ($0.60) earnings per share. What ETFs hold 2seventy bio's stock? ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Horizon Kinetics Medical ETF (MEDX) and Goldman Sachs Future Health Care Equity ETF (GDOC).Global X Genomics & Biotechnology ETF (GNOM). Who are 2seventy bio's major shareholders? 2seventy bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wedmont Private Capital (0.17%). Insiders that own company stock include Casdin Capital, Llc, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III. View institutional ownership trends. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSVT) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.